Description: NurExone Biologic Inc., a pharmaceutical company, engages in the development of novel, biologic, and minimal-invasive treatment for the spinal cord and traumatic brain injury. It develops a biological extracellular vesicles-based technology drug platform to treat damage in the central nerve system. The company was founded in 2020 and is based in Toronto, Canada.
Home Page: nurexone.com
NRX Technical Analysis
1 First Canadian Place
Toronto,
ON
M5X 1G5
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Yoram Drucker | VP of Strategic Devel. & Chairman |
| Dr. Lior Shaltiel | CEO & Director |
| Mr. Eran Ovadya M.B.A. | Chief Financial Officer |
| Mr. Eyal Flom L.L.M., M.B.A. | Legal Counsel & Director |
| Ms. Inbar Paz-Benayoun | Head of Corp. Communications |
| Gabriel Eldor | VP of Strategic Operations & Director |
| Meni Sofiof | Financial Controller |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | |
| Full Time Employees: | 0 |